@article{45fd70e9ccff4ae8b994fd1c2143a881,
title = "Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies",
abstract = "Introduction: Multiple myeloma (MM) remains an incurable disease with a median overall survival of approximately 5 years. Gain or amplification of 1q21 (1q21+) occurs in around 40% of patients with MM and generally portends a poor prognosis. Patients with MM who harbor 1q21+ are at increased risk of drug resistance, disease progression, and death. New pharmacotherapies with novel modes of action are required to overcome the negative prognostic impact of 1q21+. Areas covered: This review discusses the detection, biology, prognosis, and therapeutic targeting of 1q21+ in newly diagnosed and relapsed MM. Patients with MM and 1q21+ tend to present with higher tumor burden, greater end-organ damage, and more co-occurring high-risk cytogenetic abnormalities than patients without 1q21+. The chromosomal rearrangements associated with 1q21+ result in dysregulation of genes involved in oncogenesis. Identification and characterization of the 1q21+ molecular targets are needed to inform on prognosis and treatment strategy. Clinical trial data are emerging that addition of isatuximab to combination therapies may improve outcomes in patients with 1q21+ MM. Expert opinion: In the next 5 years, the results of ongoing research and trials are likely to focus on the therapeutic impact and treatment decisions associated with 1q21+ in MM.",
keywords = "1q21, chromosome aberrations, cytogenetic analysis, multiple myeloma, prognosis, treatment outcome",
author = "Kamlesh Bisht and Brian Walker and Kumar, {Shaji K.} and Ivan Spicka and Philippe Moreau and Tom Martin and Costa, {Luciano J.} and Joshua Richter and Taro Fukao and Sandrine Mac{\'e} and {van de Velde}, Helgi",
note = "Funding Information: This report was funded by Sanofi, Cambridge, MA, USA Medical writing support was provided by John Clarke, PhD, and Malcolm Darkes, PhD, on behalf of Elevate Medical Affairs, contracted by Sanofi Genzyme for publication support services. Funding Information: Kamlesh Bisht is an employee of Sanofi and may hold shares and/or stock options in the company; Shaji K Kumar reports receiving grants and other from BMS/Celgene, grants and other from Takeda, grants and other from Abbvie, grants and other from Roche, grants from Medimmune, grants from Tenebio, grants from Carsgen, personal fees from Oncopeptides, grants and other from Janssen, personal fees from Beigene, personal fees from Antengene, outside the submitted work. Ivan Spicka reports receiving personal fees, advisory board and speakers bureau for Amgen, Celgene, Janssen, Sanofi, BMS and Takeda; Philippe Moreau reports receiving consultancy fees and honoraria from Janssen, BMS, Celgene, Amgen, Sanofi and Abbvie; Tom Martin reports receiving research funding from Sanofi, Amgen, Seattle Genetics, JNJ and Janssen; Consultancy fees–Legend Biotech; Luciano Costa reports personal fees from Sanofi, during the conduct of the study; personal fees from Sanofi, grants and personal fees from Janssen, grants and personal fees from Amgen, grants and personal fees from BMS, GSK and oncopetides outside the submitted work; Joshua Richter reports receiving personal fees from Sanofi, Karyopharm, Janssen, BMS/Celgene, Secura Bio, Oncopeptides, X4 Pharmaceuticals, Adaptive Biotechnologies, Takeda, and Astra Zeneca, outside the submitted work; Taro Fukao, Sandrine Mace and Helgi van de Velde are employees of Sanofi and may hold shares and/or stock options in the company. Publisher Copyright: {\textcopyright} 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",
year = "2021",
doi = "10.1080/17474086.2021.1983427",
language = "English (US)",
volume = "14",
pages = "1099--1114",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "12",
}